Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations

Background Integrative analysis of endometrioid endometrial carcinoma (EEC) using multiple platforms has distinguished four molecular subgroups. However, the landscape of expressed long non-coding RNAs (lncRNA) and their role in charting EEC subgroups and determining clinical aggressiveness remain largely unknown. Materials and Methods We performed integrative analysis of lncRNAs in EEC using The Cancer Genome Atlas (TCGA) molecular RNAseq profiles of 191 primary tumors for which genomic data were also available. We established lncRNA subgroup classification, correlated it with chromatin modifying gene expression, and described correlations between our lncRNA classification and clinico-genomic tumor features. Results Using stringent criteria, we identified 1,931 expressed lncRNAs and predicted potential drivers through integrative analysis. Unsupervised clustering of lncRNA expression revealed three robust categories: basal-like, luminal-like and CTNNB1-enriched subgroups. Basal-like subgroup was enriched for aggressive tumors with higher pathological grade (p < 0.0001), TNM stage (p = 0.01), and somatic mutations in trithorax-group genes (MLL, MLL2 and MLL3); and it overexpressed polycomb genes EZH2 and CBX2. In contrast to the luminal-like subgroup, progesterone (PGR) and estrogen receptor (ESR1) genes were highly down-regulated in the EEC basal-like subgroup. Consistent with its enrichment for CTNNB1 mutations (69%), lncRNA profile of the CTNNB1-enriched EEC subgroup was highly similar to that of the CTNNB1-enriched liver cancer subgroup. Conclusions Our results reveal the utility of systematic characterization of clinically annotated EEC in three clinically relevant subgroups. They also highlight the convergence of aberrations in polycomb- and trithorax-group genes in aggressive basal EEC subtypes, providing a rationale for further investigation of epigenetic therapy in this setting.

[1]  C. Arrowsmith,et al.  Cbx2 targets PRC1 to constitutive heterochromatin in mouse zygotes in a parent-of-origin-dependent manner. , 2015, Molecular cell.

[2]  Jun Ma,et al.  Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. , 2015, Cellular signalling.

[3]  D. Bell,et al.  The mutational landscape of endometrial cancer. , 2015, Current opinion in genetics & development.

[4]  D. Moazed,et al.  RNA-mediated epigenetic regulation of gene expression , 2015, Nature Reviews Genetics.

[5]  Lei Han,et al.  Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner , 2014, Oncotarget.

[6]  W. Lam,et al.  Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role , 2014, British Journal of Cancer.

[7]  J. Weinstein,et al.  Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes , 2014, Oncotarget.

[8]  Li Ding,et al.  Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. , 2014, Journal of the National Cancer Institute.

[9]  Hui Li,et al.  Long noncoding RNA HOTAIR involvement in cancer , 2014, Tumor Biology.

[10]  X. Wan,et al.  The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. , 2014, International journal of molecular medicine.

[11]  Ulla-Maija Haltia,et al.  FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype , 2014, Journal of gynecologic oncology.

[12]  Ming-qing Li,et al.  IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8. , 2013, International journal of clinical and experimental pathology.

[13]  Gabor T. Marth,et al.  MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping , 2013, PloS one.

[14]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[15]  Nancy F. Hansen,et al.  Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes , 2012, Nature Genetics.

[16]  David G. Knowles,et al.  The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression , 2012, Genome research.

[17]  Howard Y. Chang,et al.  Genome regulation by long noncoding RNAs. , 2012, Annual review of biochemistry.

[18]  D. Aoki,et al.  Biomarkers in endometrial cancer: Possible clinical applications (Review). , 2012, Oncology letters.

[19]  A. Boyer,et al.  Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis , 2011, Oncogene.

[20]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[21]  A. Fortunato,et al.  The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease , 2010, Obstetrics and gynecology international.

[22]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[23]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[24]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[25]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[26]  D. Koller,et al.  A module map showing conditional activity of expression modules in cancer , 2004, Nature Genetics.

[27]  M. Balzi,et al.  Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A. , 2003, Cancer research.

[28]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[29]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[30]  M. Munsell,et al.  A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Lottin,et al.  The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. , 2005, European journal of cancer.

[32]  R. Kurman,et al.  A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[33]  N. Dubrawsky.  Cancer statistics , 2022 .